Search - tctmd.com

Displaying 161 - 180 of 323

Sort: Relevancy | Date

Presentation TCT 2013

Ultrasound, Radiation and Chemicals: What Constitutes a Disruptive Technology in Sympathetic Neuromodulation?

Presenter: Peter Fitzgerald

October 27, 2013

Presentation TCT 2013

The Spectrum of Current and Future Renal Denervation Clinical Trials

Presenter: Mehdi Shishehbor

October 27, 2013

Presentation TCT 2013

Strategies for Measuring Technical Success to Facilitate Ideal Patient Selection in Renal Denervation

Presenter: Paul Sobotka

October 27, 2013

Presentation TCT 2013

Selecting the Patient Most Likely to Benefit from Renal Artery Intervention

Presenter: Christopher White

October 27, 2013

Presentation TCT 2013

Renal Revascularization Data Review and Recommendations for Management

Presenter: Jeffrey Olin

October 27, 2013

Presentation TCT 2013

Renal Denervation for Glycemic Control and Obstructive Sleep Apnea: An Update

Presenter: Felix Mahfoud

October 27, 2013

Presentation TCT 2013

Renal Denervation for Congestive Heart Failure: Current Evidence and Ongoing Studies

Presenter: Justin Davies

October 27, 2013

Presentation TCT 2013

Reading the Tea Leaves: Possible Outcomes and Impact of the CORAL Trial

Presenter: Christopher Cooper

October 27, 2013

Presentation TCT 2013

Radiofrequency-Based RDN Is and Will Remain the Benchmark for RDN

Presenter: Meital Mazor

October 27, 2013

Presentation TCT 2013

Non-focused Ultrasound with the TIVUS Denervation Catheter for RDN

Presenter: Michael Jonas

October 27, 2013

Presentation TCT 2013

Moving Away From Surrogate Measures: Rationale and Design for a Clinical Outcomes Trial of Renal Artery Denervation (EnligHTNment)

Presenter: Felix Mahfoud

October 27, 2013

Presentation TCT 2013

Moderate Treatment Resistant Hypertension: A New Indication for RDN?

Presenter: David Kandzari

October 27, 2013

Presentation TCT 2013

Mesenteric Ischemia Syndromes and Treatments: An Update

Presenter: Greg Mishkel

October 27, 2013

Presentation TCT 2013

Is the Noncompliant Patient with Severe Treatment Resistant Hypertension an Appropriate Candidate for this Technology?

Presenter: Robert Whitbourn

October 27, 2013

Presentation TCT 2013

Is Renal Denervation REALLY READY for Prime Time: A Critical Appraisal

Presenter: Darrel Francis

October 27, 2013

Presentation TCT 2013

How We Should Define "Responsiveness" to Renal Denervation Therapies

Presenter: Krishna Rocha-Singh

October 27, 2013

Presentation TCT 2013

FDA Perspectives: Clinical Trial Regulatory Pathway for Renal Denervation Devices

Presenter: Andrew Farb

October 27, 2013

Presentation TCT 2013

Extra-vascular Focused Ultrasonic Denervation (Kona Medical)

Presenter: Todd Brinton

October 27, 2013

Presentation TCT 2013

Ethanol Injection for Renal Denervation (Ablative Solutions)

Presenter: Tim Fischell

October 27, 2013

Presentation TCT 2013

Electrophysiological Considerations for Renal Denervation: Implications for Arrhythmia Control

Presenter: Vivek Reddy

October 27, 2013

Advertisement

Ultrasound, Radiation and Chemicals: What Constitutes a Disruptive Technology in Sympathetic Neuromodulation?

The Spectrum of Current and Future Renal Denervation Clinical Trials

Strategies for Measuring Technical Success to Facilitate Ideal Patient Selection in Renal Denervation

Selecting the Patient Most Likely to Benefit from Renal Artery Intervention

Renal Revascularization Data Review and Recommendations for Management

Renal Denervation for Glycemic Control and Obstructive Sleep Apnea: An Update

Renal Denervation for Congestive Heart Failure: Current Evidence and Ongoing Studies

Reading the Tea Leaves: Possible Outcomes and Impact of the CORAL Trial

Radiofrequency-Based RDN Is and Will Remain the Benchmark for RDN

Non-focused Ultrasound with the TIVUS Denervation Catheter for RDN

Moving Away From Surrogate Measures: Rationale and Design for a Clinical Outcomes Trial of Renal Artery Denervation (EnligHTNment)

Moderate Treatment Resistant Hypertension: A New Indication for RDN?

Mesenteric Ischemia Syndromes and Treatments: An Update

Is the Noncompliant Patient with Severe Treatment Resistant Hypertension an Appropriate Candidate for this Technology?

Is Renal Denervation REALLY READY for Prime Time: A Critical Appraisal

How We Should Define "Responsiveness" to Renal Denervation Therapies

FDA Perspectives: Clinical Trial Regulatory Pathway for Renal Denervation Devices

Extra-vascular Focused Ultrasonic Denervation (Kona Medical)

Ethanol Injection for Renal Denervation (Ablative Solutions)

Electrophysiological Considerations for Renal Denervation: Implications for Arrhythmia Control

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content